Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Kwong, Jeffrey C ^a,b   Li, Ping ^a   Redelmeier, Donald A ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; EPIDEMIC; FEMALE; HUMAN; INFLUENZA; MALE; MORTALITY; MULTIVARIATE ANALYSIS; REGISTER; RETROSPECTIVE STUDY; RISK; TIME; TREATMENT OUTCOME;

AGED; CANADA; COHORT STUDIES; DISEASE OUTBREAKS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MULTIVARIATE ANALYSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951216706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008087     Document Type: Article

References (43)

1. Pan American Health Organization (PAHO)(2004) Final report of the XVI Meeting on Vaccine Preventable-Diseases of the Pan American Health Organization.
2. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH, (2006) Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 368: 2211-2218.
3. (2009) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO.
4. Fedson DS, (2008) Confronting an influenza pandemic with inexpensive generic agents: can it be done? The Lancet Infectious Diseases 8: 571-576.
5. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al.(2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
6. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al.(2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
7. Lee N, Wong CK, Chan PK, Lun SW, Lui G, et al.(2007) Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 45: 723-731.
8. Peiris JS, de Jong MD, Guan Y, (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20: 243-267.
9. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, et al.(2005) Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46: 377-386.
10. Bessler H, Salman H, Bergman M, Straussberg R, Djaldetti M, (2005) In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin Immunol 117: 73-77.
11. Tousoulis D, Antoniades C, Vassiliadou C, Toutouza M, Pitsavos C, et al.(2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7: 1126-1132.
12. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, et al.(2004) Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177: 161-166.
13. Li JJ, Chen XJ, (2003) Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 14: 329-334.
14. Jialal I, Stein D, Balis D, Grundy SM, Ms-Huet B, et al.(2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935.
15. Rosenson RS, Tangney CC, Casey LC, (1999) Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353: 983-984.
16. de BN, Netea MG, Rovers C, Smilde T, Demacker PN, et al.(1998) LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. Atherosclerosis 139: 147-152.
17. Jialal I, Miguelino E, Griffen SC, Devaraj S, (2007) Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab 92: 3136-3140.
18. Almog Y, Shefer A, Novack V, Maimon N, Barski L, et al.(2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885.
19. Liappis AP, Kan VL, Rochester CG, Simon GL, (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33: 1352-1357.
20. Hackam DG, Mamdani M, Li P, Redelmeier DA, (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367: 413-418.
21. Mortensen EM, Restrepo MI, Anzueto A, Pugh J, (2005) The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 6: 82.
22. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, et al.(2006) Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 61: 957-961.
23. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR, (2007) Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27: 325-332.
24. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, et al.(2008) Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. European Respiratory Journal 31: 611-617.
25. Chalmers JD, Singanayagam A, Murray MP, Hill AT, (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. American Journal of Medicine 121: 1002-1007 e1.
26. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, et al.(2008) Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Archives of Internal Medicine 168: 2081-2087.
27. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ, (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333: 999.
28. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, et al.(2009) Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 338: b2137.
29. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS, (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology 35: 337-344.
30. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D, (2003) Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10: 67-71.
31. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA, (1999) Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Canadian Journal of Cardiology 15: 1277-1282.
32. Naylor CD, Slaughter P, (1999) Cardiovascular health and services in Ontario: an ICES atlas.
33. Chan B, (1999) Supply of physicians' services in Ontario.
34. Iron K, Zagorski BM, Sykora K, Manuel DG, (2008) Living and dying in Ontario: an opportunity for improved health information. ICES Investigative Report.
35. Kwong JC, Manuel DG, (2007) Using OHIP physician billing claims to ascertain individual influenza vaccination status. Vaccine 25: 1270-1274.
36. Hux JE, Ivis F, Flintoft V, Bica A, (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512-516.
37. Hall R, Coyte P, (2001) Determinants of home care utilization: who uses home care in Ontario? Canadian Journal of Aging 20: 175-192.
38. Public Health Agency of Canada(2006) Canadian Immunization Guide. Her Majesty the Queen in Right of Canada Ottawa.
39. Starfield B, Weiner J, Mumford L, Steinwachs D, (1991) Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 26: 53-74.
40. Rosenbaum PR, Rubin DB, (1984) Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. Journal of the American Statistical Association 79: 516-524.
41. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, et al.(2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119: 2051-2057.
42. Ko DT, Mamdani M, Alter DA, (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291: 1864-1870.
43. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, et al.(2007) Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297: 278-285.